Alx Oncology Holdings (ALXO) Free Cash Flow (2019 - 2026)
Alx Oncology Holdings (ALXO) reported Free Cash Flow of -$18.7 million for Q1 2026, up 24.37% on a YoY basis from -$15.0 million in Q1 2025, and up 1.74% sequentially from -$19.0 million in Q4 2025.
Alx Oncology Holdings (ALXO) Free Cash Flow (2019 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 8 years of Free Cash Flow data on file, last reported at -$18.7 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 24.37% year-over-year to -$18.7 million; the trailing twelve-month figure through Mar 2026 stood at -$78.3 million (up 28.15% YoY), and the FY2025 full-year result was -$84.4 million, up 31.06% from the prior year.
- Free Cash Flow rose to -$18.7 million in Q1 2026, from -$19.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$17.1 million in Q3 2025 to a low of -$39.8 million in Q4 2023.
- A 5-year average of -$26.3 million and a median of -$25.5 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow slumped 313.52% in 2022 and jumped 40.73% in 2025, its largest moves.
- Tracing ALXO's Free Cash Flow over 5 years: stood at -$21.2 million in 2022, then slumped by 87.69% to -$39.8 million in 2023, then advanced by 19.38% to -$32.1 million in 2024, then jumped by 40.73% to -$19.0 million in 2025, then gained by 1.74% to -$18.7 million in 2026.
- Business Quant data shows ALXO's Free Cash Flow at -$18.7 million in Q1 2026, -$19.0 million in Q4 2025, and -$17.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | -18.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.70 Mn |
| Mar 31, 2026 | -18.70 Mn |
| Dec 31, 2025 | -19.03 Mn |
| Dec 31, 2025 | -19.03 Mn |
| Sep 30, 2025 | -17.15 Mn |
| Sep 30, 2025 | -17.15 Mn |
| Jun 30, 2025 | -23.45 Mn |
| Jun 30, 2025 | -23.45 Mn |
| Mar 31, 2025 | -24.72 Mn |
| Mar 31, 2025 | -24.72 Mn |
| Dec 31, 2024 | -32.11 Mn |
| Dec 31, 2024 | -32.11 Mn |
| Sep 30, 2024 | -25.53 Mn |
| Sep 30, 2024 | -25.53 Mn |
| Jun 30, 2024 | -26.66 Mn |
| Jun 30, 2024 | -26.66 Mn |
| Mar 31, 2024 | -38.07 Mn |
| Mar 31, 2024 | -38.07 Mn |
| Dec 31, 2023 | -39.83 Mn |
| Dec 31, 2023 | -39.83 Mn |